Tasso, Inc.

Tasso, Inc. is a Seattle-based startup providing life-changing, actionable insights in the health care industry. Founded in 2011, the company focuses on at-home diagnostic testing, revolutionizing blood collection with a goal to make clinical-grade, convenient diagnostic tests accessible to a wide range of users. Its innovative approach has gained traction with leading health systems, clinical research organizations, and academic medical centers. Tasso's product has been utilized in pharmaceutical clinical trials, by Olympians for a virtual anti-doping program, and adopted broadly by hospital systems across the US. The company received a significant $100.00M Series B investment on 16 December 2021. This investment was backed by prominent names in the investment world, including RA Capital Management, The Cedars-Sinai Accelerator, Senvest Capital, D. E. Shaw, Foresite Capital, InCube Ventures, J2 Ventures, SIB Innovations- und Beteiligungsgesellschaft, Hambrecht Ducera Growth Ventures, and the Merck Global Health Innovation Fund. Tasso's focus on disruptive innovation in the health care industry, backed by significant investments from renowned firms, positions it as a key player in the evolving landscape of at-home diagnostic testing.